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Abstract
Background: Complement factor C5 can either aggravate or attenuate the T-helper type 2 (TH2) immune response
and airway hyperresponsiveness (AHR) in murine models of allergic asthma. The effect of C5 during the effector
phase of allergen-induced asthma is ill-defined.
Objectives: We aimed to determine the effect of C5 blockade during the effector phase on the pulmonary TH2
response and AHR in a house dust mite (HDM) driven murine asthma model.
Methods: BALB/c mice were sensitized and challenged repeatedly with HDM via the airways to induce allergic
lung inflammation. Sensitized mice received twice weekly injections with a blocking anti-C5 or control antibody
24 h before the first challenge.
Results: HDM challenge in sensitized mice resulted in elevated C5a levels in bronchoalveolar lavage fluid. Anti-C5
administered to sensitized mice prior to the first HDM challenge prevented this rise in C5a, but did not influence
the influx of eosinophils or neutrophils. While anti-C5 did not impact the recruitment of CD4 T cells upon HDM
challenge, it reduced the proportion of TH2 cells recruited to the airways, attenuated IL-4 release by regional lymph
nodes restimulated with HDM ex vivo and mitigated the plasma IgE response. Anti-C5 did not affect innate
lymphoid cell (ILC) proliferation or group 2 ILC (ILC2) differentiation. Anti-C5 attenuated HDM induced AHR in the
absence of an effect on lung histopathology, mucus production or vascular leak.
Conclusions: Generation of C5a during the effector phase of HDM induced allergic lung inflammation contributes
to TH2 cell differentiation and AHR without impacting ILC2 cells.
Keywords: Complement system, Asthma, Allergic lung inflammation, House dust mite
Background
Asthma is a heterogeneous disease characterized by
airway hyperresponsiveness (AHR) and usually chronic
airway inflammation dominated by a T-helper type 2
(TH2) response [1, 2]. The vast majority of allergic
asthma patients are sensitized to house dust mite
(HDM) and exposure to this abundantly present allergen
causes respiratory symptoms such as coughing, wheez-
ing and reversible airway obstruction [3].
The complement system is an important part of the in-
nate immune system and consists of a network of proteins
that when activated releases proteolytic fragments with
pro-inflammatory properties. Activation of the comple-
ment system can occur through three pathways (i.e., the
classical, lectin and alternative pathways), which lead to
downstream proteolytic cleavage of C3 and C5, resulting
in the release of the anaphylatoxins C3a and C5a [4, 5].
Recent investigations revealed a novel role for these
anaphylatoxins and their receptors in the pathogenesis of
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asthma [6, 7]. In asthma patients, elevated levels of C3a
and C5a were detected in the airways following allergen
challenge [8]. While C3a signaling aggravates AHR [9]
and drives allergic inflammation in different asthma
models [10–12], C5a can exert both protective and detri-
mental effects during the course of an allergic inflamma-
tion. Prior to allergen sensitization, genetic deletion or
pharmacological blockade of C5 or the C5a receptor
(C5aR) resulted in a strongly enhanced allergic phenotype
[13, 14]. Mechanistically, C5a/C5aR signaling regulated
dendritic cells (DC) function, thereby favoring plasmacy-
toid DCs to suppress T-cell activation [13]. In addition,
C5a/C5aR signaling in myeloid DCs hampered production
of the chemokines CCL17 and CCL22, leading to an
impaired recruitment of TH2 cells into the lung [15]. Fur-
thermore, C5a/C5aR signaling can induce IL-12 produc-
tion in antigen presenting cells and potentiates skewing
toward TH1 responses [16]. In contrast, eliminating C5a/
C5aR signaling after the sensitization phase reduced
allergic lung inflammation [17] and AHR [18, 19]. The
underlying mechanisms for this C5a mediated proallergic
effect in an established inflammation environment is not
well understood.
Group 2 Innate lymphoid cells (ILC2s) have been
recognized to play an important role in type 2 immune
responses [20, 21]. As an innate counterpart of TH2
cells, ILC2s orchestrate the allergic immune response by
producing TH2 associated cytokines (IL-5 and IL-13)
and presenting antigen to naïve T-cells for an effective
TH2 cell development [22]. In the absence of T and B
cells, the presence of ILC2s is sufficient to initiate and
maintain an allergic lung inflammation and AHR in
distinct mouse asthma models [23], emphasizing the
significant contribution of ILC2s to the hallmarks of
asthma. In earlier experimental asthma models blocking
the C5a/C5aR axis, the type 2 response was primarily at-
tributed to TH2 cells without assessing the contribution
of ILC2s [13, 18]. We here studied the effect of C5
inhibition during the effector phase on the type 2
responses in the lung and AHR in a HDM induced
asthma model.
Material and methods
Mice
Female BALB/c mice (8–12 weeks old) were purchased
from Charles River (Maastricht, the Netherlands). Mice
were housed under specific pathogen-free conditions
receiving food and water ad libitum. All experiments
were approved by the Animal Care and Use Committee
of the Academic Medical Center.
HDM asthma model
To induce allergic lung inflammation in mice, repeated
HDM extract intranasal challenges were performed as
described previously [24]. Briefly, mice were sensitized
on day 0, 1, 2 and challenged on day 14, 15, 18, 19 with
25 μg HDM extract (Greer Laboratories, Lenoir, N.C.,
USA) or sterile saline. Prior to intranasal administration
of HDM, all mice were anesthetized with isoflurane.
BALB/c mice were injected intraperitoneally with a rat
anti-mouse C5 monoclonal antibody (clone BB5.1; 1 mg/
mouse) [25] or an irrelevant control antibody twice
weekly (on days 13, 14, 17 and 18) during the challenge
phase. Mice were euthanized 24 h after the last chal-
lenge. In all experiments citrate blood was collected
from the vena cava inferior (4:1 v/v) and bronchoalveolar
lavage (BAL) fluid was collected by airway lumen lavage
with 2 × 0.5 ml PBS containing 10 mM EDTA, 10mM
benzamidine and 0.2 mg/ml soy bean trypsin inhibitor as
described [24]. Cell counts were measured using a
hemocytometer (Beckman Coulter, Fullerton, CA, USA)
and cell differentiation was made by flow cytometric
analysis. In one experiment the lavaged lungs were
minced, followed by enzymatic digestion in RPMI
medium with 5% Fetal Bovine Serum, 1% penicillin/
streptomycin, liberase™ and DNAse at 37 °C for 30 min.
Next, incubated cells were dissociated by aspiration
through a 19-gauge needle to obtain single cells.
Erythrocytes were lysed with sterile lysis buffer (Qiagen,
Hilden, Germany). Unflushed lung, collected in a separ-
ate experiment, was used for pathology examination to
avoid structural disruption as a consequence of BAL.
Measurement of enhanced pause (PenH)
PenH was measured at day 19 by whole-body ple-
thysmograph in conscious mice (Buxco Electronics,
Troy, NY, USA) as described [24]. Mice were first
subjected to aerosolized saline to determine nonspecific
responsiveness, followed by increasing concentrations of
aerosolized methacholine (3.1, 12.5, 25 and 50mg/mL in
saline for 3 min; Sigma-Aldrich). For each methacholine
dose PenH values were measured over five minutes.
Flow cytometry
Cells in BAL fluid were stained with CD3 FITC, CD11c
PercP, Siglec F Alexa 647, CD11b PE-Cy7, viability dye
APC Cy7 (all BD Biosciences, San Jose, CA, USA), Ly6G
Alexa700 (Biolegend, San Diego, CA, USA), MHCII PE,
and CD45 PE-eFluor610 (eBiosciences, San Diego, CA,
USA) in the presence of Fc blocker (CD16/CD32, eBios-
ciences). Single cell suspensions from lungs were stained
with CD4 FITC, CD45 PerCP-Cy5.5 (eBiosciences),
GATA-3 Alexa 647, and viability dye APC-Cy7 (BD
Biosciences). The following markers were used for the
analysis of ILCs in lung tissue: Lineage (Lin) markers
including CD3e, CD19, GR1, B220, Ter119, FcaR1 (all
FITC, Biolegend), CD45 Alexa700, CD90 PE, ST2
Brilliant Violet 421 (Biolegend), CD49b PE-Cy7
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(eBiosciences) and CD3 Percp-Cy5.5 (BD biosciences).
Mediastinal lymph nodes (mLN) cells were stained with
CD45 PerCP-Cy5.5, CD4 FITC, GATA-3 Alexa 647 (BD
Biosciences) and IL-4 APC (Biolegend). For intracellu-
lar/intranuclear staining, cells were permeabilized and
fixed using a FOXp3 Staining Buffer set (eBioscience)
and subsequently stained with the appropriated
markers. All appropriate Fluorescence Minus One
(FMO) controls were used. Data were collected on a
BD Biosciences Canto II flow cytometer or BD FAC-
SAria™ III and analyzed using FlowJo software (Trees-
tar, Palo Alto, CA, USA).
Assays
C5a was measured in BAL fluid by ELISA. Purified rat
anti-mouse C5a (clone I52–1486) was used as capture
antibody, purified recombinant mouse C5a as standard
and biotinylated rat anti-mouse C5a (clone I52–278) as
detection antibody (all from BD Biosciences). Cytokines
(IL-4, IL-5, IL-13), myeloperoxidase (MPO) and elastase
were measured by ELISA (R&D systems, Minneapolis,
MN, USA). Plasma total IgE was determined using rat-
anti-mouse IgE as a capture antibody, purified mouse
IgE as a standard, and biotinylated rat-anti-mouse IgE as
detection (all from BD Biosciences) as described [24].
Plasma HDM-specific IgG1 was determined using HDM
as capture and biotinylated rat-anti-mouse IgG1 as de-
tection (BD Biosciences). BAL fluid IgM was determined
as described [24], using rat-anti-mouse IgM as capture
antibody, purified mouse IgM as standard and biotinyl-
ated goat-anti-mouse IgM (all from BD Biosciences) as
detection. Total protein in BAL fluid was measured
using Bio-Rad protein assay (Bio-Rad Laboratories,
Veenendaal, Netherlands).
Ex vivo stimulation of mediastinal lymph nodes (mLN)
Stimulations of mLN ex vivo were performed as
described [24]. Briefly, mLN were harvested 24 h after
the last challenge and filtered through 100 μm strainers.
Single cells were seeded at a density of 2 × 105 cells/well
in 96-well round bottom plates (Greiner Bio-One,
Alphen a/d Rijn, Netherlands) and incubated with 25 μg/
ml HDM or PBS for four days at 37 °C with 5% CO. Su-
pernatants were collected and stored at − 80 °C until
analysis. In a separate experiment IL-4 production by
CD4 T-cells in mLN were determined. To that end,
mLN cells were stimulated with PMA (10 ng/ml) and
ionomycin (1500 ng/ml; both Sigma-Aldrich) for five
hours in the presence of Golgiplug (BD Biosciences) for
the final three hours.
Histology
Histological analysis was performed as described [24].
Briefly, after fixation in 10% formalin, four μm thick
sections were stained with Hematoxylin and Eosin
(H&E) to determine allergic inflammation properties
such as edema, endothelialitis, peribronchial and
perivascular inflammation and interstitial inflammation
on a scale from 0 to 4 (0: absent; 1: mild; 2: moderate; 3:
severe; 4: very severe). To examine mucus production,
sections were stained with Periodic acid-Schiff (Pas-D)
and scored for extent of goblet cells and mucous plugs
on a scale from 0 to 3. Slides were coded and scored by
a pathologist in a blinded fashion.
Statistical analysis
Data were analyzed by Mann-Whitney U-test for com-
parison between groups. Two-way analysis of variance
test followed by Tuckey’s multiple comparison test was
used for groups of three or more. Experimental groups
consisted of 6–8 mice. P ≤ 0.05 was considered statisti-
cally significant. All statistical analyses were performed
using GraphPad Prism 7.
Results
C5 inhibition does not modify leukocyte influx in the
airways upon HDM challenge
To investigate the contribution of C5 activation to allergic
lung inflammation HDM sensitized mice were treated with
a neutralizing anti-C5 mAb during repeated HDM chal-
lenges via the airways. HDM challenge resulted in in-
creased C5a levels in BAL fluid. Treatment with anti-C5
mAb during the challenge phase reduced HDM-induced
C5a concentrations to levels detected in unchallenged mice
(Fig. 1a). Repeated HDM challenge triggered an influx of
leukocytes into BAL fluid (Fig. 1b),which was the result of
recruitment of eosinophils (Fig. 1c) and neutrophils (Fig.
1d). The number of alveolar macrophages in BAL fluid was
lower in HDM challenged mice when compared with con-
trol animals (Fig. 1e). Anti-C5 did not modify leukocyte
numbers or composition in BAL fluid. HDM challenge
also caused neutrophil degranulation, as reflected by ele-
vated concentrations of MPO and elastase in BAL fluid;
this response was not altered by anti-C5 (Fig. 2a, b).
C5 inhibition reduces TH2 but not ILC2 cell numbers
following HDM challenge
ILC2s and TH2 cells are both essential for the initiation and
propagation of a type 2 immune response in allergic airway
inflammation [22]. Therefore, we determined whether C5
inhibition influences the influx or expansion of these cells
upon HDM challenge in sensitized mice. Total ILCs were
defined as CD45+Lin−CD3−CD49b−CD90+ cells, and within
the total ILC population, ILC2s were further identified by
expression of ST2 (Additional file 1: Figure S1). C5 inhib-
ition during the challenge phase did not affect the propor-
tion of total ILC or ILC2s in the lungs (Fig. 3a). Likewise,
the percentage of CD4 T-cells in the lungs was similar
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between the anti-C5 treated and control group follow-
ing HDM challenge (Fig. 3b). However, the percentage
of TH2 cells, defined as CD4
+GATA-3+ cells, within
the total CD4 T-cell population (Additional file 2:
Figure S2) was significantly lower in anti-C5 treated
mice.
C5 inhibition reduces type 2 responses to HDM
To further evaluate type 2 responses, we measured
TH2 cytokines in BAL fluid and supernatants of
mLNs re-stimulated with HDM. As expected, HDM
challenge elicited enhanced IL-5 and IL-13 release in
BAL fluid compared with saline controls (Fig. 4a, b).
C5 inhibition did not alter the levels of these TH2
cytokines in BAL fluid. IL-4 remained below detection
limit in BAL fluid, consistent with previous results
from our group [24]. Re-stimulation of mLNs
obtained from HDM challenged mice with HDM
resulted in release of IL-4, IL-5 and IL-13 (Fig. 5a-c).
C5 inhibition during the HDM challenge phase was
associated with diminished IL-4 release by mLN upon
re-exposure to HDM, while IL-5 and IL-13 release
were not modified. The attenuated IL-4 release by
mLN in C5 inhibited mice was accompanied by
reduced intracellular IL-4 production by mLN derived
CD4 T-cells (Fig. 5d) and a lower proportion of
Fig. 1 C5 inhibition does not modify leukocyte influx in the airways. Mice were injected intraperitoneally with anti-C5 or control antibody twice
weekly during the challenge phase. (a) C5a concentration in bronchoalveolar lavage fluid (BALF) from saline (NaCl) or HDM challenged mice.
(b) Total cell count in BALF. (c-e) Percentage of eosinophils, neutrophils and alveolar macrophages in BALF. Data are expressed as means ± SEM
(n = 6–8 per group). ##P < 0.01, ***P < 0.001 for comparison between NaCl and HDM within control or anti-C5 antibody injected mice
Fig. 2 C5 inhibition does not alter neutrophil degranulation. (a) Myeloperoxidase and (b) elastase concentration in bronchoalveolar lavage fluid
(BALF). All data are presented as means ± SEM (n = 6–8 per group). ***P < 0.001 for comparison between NaCl and HDM within control or
anti-C5 mice
Yang et al. Respiratory Research          (2019) 20:165 Page 4 of 10
CD4+GATA-3+ T-cells in mLN (Fig. 5e). During aller-
gic inflammation, IL-4 mediates the class switch re-
combination of IgM to IgE and IgG1 in B-cells [22].
Repeated HDM challenge led to elevated plasma IgE
and HDM-specific IgG1 concentrations (Fig. 6a, b).
C5 inhibition reduced total IgE and tended to lower
HDM-specific IgG1 (P = 0.08). Together these data
show that C5 inhibition during the HDM challenge
phase attenuates type 2 responses without affecting
ILC2s.
C5 inhibition does not modify lung pathology following
HDM challenge
This model of HDM induced allergic inflammation
reproduces important features of asthma such as peri-
vascular and interstitial inflammation, peribronchitis,
endothelialitis and oedema, as well as mucus produc-
tion [24] (Fig. 7a, b). Anti-C5 treated mice displayed
HDM-induced lung inflammation to the same extent
as control mice, as reflected by the semi-quantitative
scoring system described in the Methods section.
Likewise, HDM challenge evoked mucus production
was unaltered in anti-C5 administered mice. Comple-
ment C5 has been implicated to play a role in vascu-
lar permeability [26, 27]. We measured total protein
and IgM in BAL fluid as measures for vascular leak.
C5 inhibition in HDM challenged mice did not at-
tenuate allergen induced vascular leak (Fig. 7c, d).
C5 inhibition reduces airway hypersensitivity as measured
by PenH
To obtain insight into the potential functional conse-
quences of attenuated TH2 responses in C5 inhibited
mice, we measured PenH as a marker for AHR (Fig. 8).
Consistent with our previous studies [24] HDM
sensitization and challenge elicited enhanced AHR in
comparison to saline challenge. C5 inhibition signifi-
cantly attenuated allergen induced AHR.
Fig. 3 C5 inhibition reduces TH2 cells but not ILC2 following HDM challenge. Flow cytometry analysis of group 2 innate lymphoid cells (ILC2)
and T-helper 2 cells (TH2) in lung tissue. All cells depicted here are pre-gated as single, viable and CD45
+ cells. (A) Total ILCs were defined as
CD45+Lin−CD3−CD49b− CD90+ cells. Within the total ILC population ST2+ cells were regarded as ILC2 cells. (B) Total T-helper cells were defined as
CD45+CD4+ cells. TH2 cells within total T-helper cell population stain positive for the transcription factor GATA-3. All data are means ± SEM
(n = 8 per group). #P < 0.05 ***P < 0.001 for comparison between NaCl and HDM within control or anti-C5 mice
Fig. 4 C5 inhibition does not modulate cytokine release in BALF following HDM challenge. (a, b) IL-5, IL-13 in bronchoalveolar lavage fluid (BALF)
Data are depicted as means ± SEM (n = 6–8 per group). ***P < 0.001 for comparison between NaCl and HDM within control or anti-C5 mice
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Discussion
The anaphylatoxin C5a has been unveiled to play an
important role in orchestrating the maladaptive TH2
immune response in murine asthma models [15, 16].
The mechanism by which C5a amplifies TH2 inflamma-
tion in an inflamed pulmonary environment is unclear.
In the present study we demonstrate that C5 inhibition
during the effector phase does not modulate the
proportion of ILC2s but decreases TH2 cells in the lung
and mLN, which is accompanied by reduced type 2
responses and an attenuated AHR.
Our HDM driven asthma model reproduces important
features of allergic asthma such as pulmonary TH2
inflammation, AHR and airway mucus production [28].
In accordance with similar asthma models, HDM
elicited an expansion of both ILCs and TH2 cells in the
Fig. 5 C5 inhibition mitigates IL-4 production and percentage of TH2 cell in the mLN following HDM challenge. Mediastinal lymph nodes (mLN)
were harvested from HDM sensitized and challenged mice in both control and anti-C5 groups. In one experiment mLN cells were stimulated
with either saline (NaCl) or HDM for four days. In cell-free supernatants the cytokines IL-4, IL-5 and IL-13 (a-c) were measured. In a separated
experiment mLN cells were incubated with PMA and ionomycin in the presence of Golgiplug, followed by intracellular staining of IL-4 (d) and
intranuclear staining of GATA-3 (e). Data are depicted as means ± SEM (n = 6–8 per group). #P < 0.05, ##P < 0.01, ***P < 0.001 for comparison
between NaCl and HDM within control or anti-C5 mice
Fig. 6 C5 inhibition reduces immunoglobulin release in plasma following HDM challenge. (a) IgE concentration and (b) absorbance (OD450) of
HDM-specific IgG1 in plasma. Data are express as means ± SEM (n = 6–8 per group). #P < 0.05, **P < 0.01 and ***P < 0.001 for comparison
between NaCl and HDM within control or anti-C5 mice
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lungs [29, 30]. We here demonstrate for the first time that
C5 inhibition during the effector phase does not modify
the total ILC or ILC2 population in the lung, indicating
that C5a signaling is not involved in ILC proliferation or
differentiation. This finding is consistent with a study
showing the lack of C5aR expression on ILC2s [31], ren-
dering direct C5a signaling unlikely. Furthermore, specific
deletion of C5aR on cells expressing the LysM promoter
(such as neutrophils, macrophages and dendritic cells) in
an OVA-model showed an equally strong increase in aller-
gen evoked ILC2 cells compared to wild-type mice [32].
Our data indicate explicitly that C5 blockade during the
effector phase hampers the differentiation of TH2 cells,
resulting in reduced IL-4 production in mLN with un-
altered IL-5 and IL-13 BALF levels. This discrepancy in
TH2 cytokines has also been observed in previous studies
in which C5aR was blocked during the effector phase in a
murine asthma model [13, 18]. While the exact
Fig. 7 C5 inhibition does not alter lung pathology and vascular permeability following HDM challenge. (a) Total pathology score of hematoxylin
and eosin (H&E) stained lung sections (× 4 magnification) from control (black bar) and BB5.1 (white bar) treated mice and (b) total mucus score of
PAS-D stained lung sections(× 4 magnification) (n = 6–8 per group). Protein leakage was assessed using (c) total protein and (d) IgM in BALF (n =
6–8 per group). **P < 0.01 and ***P < 0.001 for comparison between NaCl and HDM within control or anti-C5 mice
Fig. 8 C5 inhibition attenuates AHR following HDM challenge.
Airway hypersensitivity (AHR) expressed as enhanced pause (PenH)
after dose-response to methacholine (Mch) exposure on day 19.
Data are presented as means ± SEM (n = 6–8 per group). **P < 0.01
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mechanism remains enigmatic, our data suggest that ILC2
derived IL-5 and IL-13 may have compensated a presum-
able lower IL-5 and IL-13 release from reduced TH2 cells
numbers. Indeed, several studies reported enhanced IL-5
and IL-13 secretion by expanding ILC2s [33, 34], while
ILC2s are generally considered either not to produce IL-4
[20, 22] or produce it in negligible amounts [35]. We
found that C5 inhibition impeded IL-4 production in
mLN which was associated with decreased plasma IgE
and HDM-specific IgG1 responses. This finding is corrob-
orated by a study which prevented C5 activation during
the effector phase in an OVA-induced asthma model [19].
Conversely, abrogating C5 activation prior to sensitization
yielded enhanced IgE production [14], emphasizing the
time dependent dual character of C5a signaling during al-
lergic inflammation. Remarkably, previous investigations
demonstrated decreased eosinophil numbers without af-
fecting IL-5 release in the airways following C5a signaling
blockade [13, 18, 19]. The mechanism behind this dispar-
ity was not addressed. In our study, the absence of an ef-
fect on IL-5 and the eosinophil attractant CCL11 (data
not shown) by anti-C5 treatment corresponded with a
lack of differences in total leukocyte, especially eosinophil,
influx in the airways. The unaltered airway leukocyte re-
cruitment is in contrast to studies that likewise investi-
gated C5a signaling in established asthma. Different
allergens (i.e. OVA [19] or Aspergillus fumigatus [18])
used in these studies may have contributed. C5aR an-
tagonists appeared to be potent to mitigate allergen
induced leukocytes infiltration, including eosinophils,
neutrophils and lymphocytes [13, 18] while blocking
the anaphylatoxin C5a only limits neutrophil influx
[19] or fails to affect leukocyte influx as shown by
this study. Beside eosinophils, neutrophils express
C5aR (CD88) on their cell membrane making direct
C5a signaling possible [31]. C5a has been shown to
be chemotactic for neutrophils and to promote re-
lease of neutrophil intracellular content [36]. None-
theless, data from present study contradict an effect
of C5a on neutrophil recruitment and neutrophil
degranulation in HDM induced lung inflammation.
Consistent with earlier studies eliminating C5a/C5aR
signaling during the effector phase [13, 18, 19], we ob-
served an attenuated AHR in sensitized anti-C5 treated
mice. Multiple factors may have contributed to this find-
ing. First, a decreased total IgE concentration due to C5
inhibition could impair mast cell degranulation and con-
sequently mast cell derived histamine induced broncho-
constriction. As C5a is an activator of mast cells,
inhibited C5a activity could also influence AHR in a
mast cell dependent manner [15]. Alternatively, C5a
might aggravate AHR directly via activation of the C5aR
on bronchial smooth muscle cells [37]. Our data argue
against TH2 cytokine mediated attenuation of AHR,
since IL-13 is essential for the regulation of AHR [38]
and unaffected by C5 inhibition. IL-4 and IL-13 express
high resemblance and transmit signals via shared func-
tional receptor complexes (IL-4Rα/IL-13Rα1) [38]. Des-
pite these similarities, a number of in vivo functional
experiments have shown that IL-4 and IL-13 facilitate
different features of allergic asthma. Specifically, IL-4 is
regarded a regulator of TH2 cell proliferation and IgE
synthesis [39–41] while IL-13 is thought to mediate
AHR, mucus production, airway smooth muscle thicken-
ing and sub-epithelial fibrosis [42–45]. In accordance
with the unaltered IL-13 concentration in BAL fluid, C5
inhibition did not modulate HDM induced mucus
production. Although activation of C5 has been shown
to enhance vascular permeability [46], C5 inhibition did
not modulate vascular permeability in our HDM in-
duced asthma model.
As result of C5 inhibition we observed reduced C5a
levels which implies a simultaneously reduced formation
of the membrane attack complex (MAC), since the
assembly of the MAC occurs after cleavage of C5 into
C5a and C5b [4]. While MAC drives numerous proin-
flammatory events and regulates cell signaling, its role in
asthma has not been studied and the contribution of
MAC in HDM-induced responses remains to be
elucidated.
We used unrestrained whole body plethysmography
(PenH) as measure for AHR. The use of this tool to
measure airway resistance is under debate. However,
the merit of this technique has been shown in various
mouse models in which PenH results correlate well
with results from invasive measurement techniques
[47–49]. A close correlation between invasive mea-
surements and whole body plethysmography has been
validated in a comparable HDM induced asthma
mouse model [48]. Moreover, AHR, measured by in-
vasive methods, is enhanced following HDM challenge
in models resembling ours [50, 51]. Nonetheless, in-
terpretation of our Penh data without validation by
invasive measurements is a limitation of this study.
Conclusion
In conclusion, our data demonstrate that comple-
ment C5 activation during the challenge phase drives
TH2 responses via TH2 cells but not ILC2s and ag-
gravates allergen induced AHR. Further research is
warranted to elucidate the underlying mechanisms of
the C5a mediated effect on IL-4 production. Despite
the promising beneficial effect of C5 inhibition on
airway inflammation and AHR in murine asthma
models, clinical investigations are needed to evaluate
the therapeutic potential of C5 inhibition in asthma
patients.
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Additional files
Additional file 1: Figure S1. Gating strategy for ILCs and ILC2s. Flow
cytometry plots of lung tissue from (A) NaCl or (B) HDM challenged mice.
From left to right; within the lymphocyte gate, single CD45 positive and
viable cells expressing CD3−CD49b−Lin−CD90+ were defined as ILCs. Cells
expressing ST2 positivity within the ILC population were defined as ILC2s.
(PDF 206 kb)
Additional file 2: Figure S2. Gating strategy for CD4 T-cells and TH2
cells. Flow cytometry plots of lung tissue from (A) NaCl or (B) HDM
challenged mice. From left to right; within the lymphocyte gate, single
CD45 positive and viable cells expressing CD4 positivity were defined as
CD4 T-cells. Cells expressing GATA-3 positivity within the CD4 population
were defined as TH2 cells. (PDF 229 kb)
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AHR: Airway hyperresponsiveness; BAL: Bronchoalveolar lavage; C5aR: C5a
receptor; DC: Dendritic cells; H&E: Hematoxylin and Eosin; HDM: House dust
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mAb: Murine antibody; mLN: Mediastinal lymph nodes; PenH: Enhanced
pause; TH2: T-helper type 2
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